Home » Covidien: FDA Extends Review of Opioid Pain Drug
Covidien: FDA Extends Review of Opioid Pain Drug
Covidien Plc said U.S. health regulators extended the review period of its experimental
opioid pain drug by three months to Feb. 22, 2010.
Forbes
Forbes
Upcoming Events
-
07May
-
14May
-
30May